Drs. R.V. Paul Chan and Yoshihiro Yonekawa join the Clinical Advisory Board with Leslie D. MacKeen, Product Manager at Phoenix at the helm.
PLEASANTON, Calif. (PRWEB) December 05, 2019
Today, Phoenix Technology Group™, LLC (Phoenix), a leading provider of advanced ophthalmic imaging solutions, announced the addition of new Clinical Advisory Board (CAB) members to further inform the Company’s focus on innovation and product development.
The new CAB members are:
- R.V. Paul Chan, MD, MSc, MBA, FACS, Professor and Head of the Department of Ophthalmology and Visual Sciences; Director of the Pediatric Retina and Retinopathy of Prematurity Service at the Illinois Eye and Ear Infirmary, University of Illinois College of Medicine, Chicago.
- Yoshihiro Yonekawa, MD adult and pediatric retinal specialist at Wills Eye Hospital and Mid Atlantic Retina, Philadelphia.
The CAB is made up of leading physicians and ophthalmic photographers, with diverse and relevant areas of expertise to Phoenix to help inform future strategic development of the Company’s clinical products. This includes input and advice on product direction for the Phoenix ICON™ retinal imaging camera, the Phoenix CONNECT telemedicine platform, and advanced technology and algorithm development.
“We are excited about the addition of these leading physicians to our advisory board,” said Scott Carr, chairman and CEO of Phoenix. “Dr. Chan is a leading pediatric retina specialist and has proven innovation experience in improving global health through telemedicine and tele-education programs, and he has been at the forefront of research in developing imaging technologies and artificial intelligence in ophthalmology. Dr. Yonekawa brings expertise in both adult and pediatric retinal issues, has contributed to over 250 original papers and publications and achieved numerous high-profile awards for his work.” says CEO, Scott Carr. “These are world-class ophthalmologists and their advice, as we continue to advance our products and technology, is invaluable.”
Leslie D. MacKeen, BSc, CRA rejoined Phoenix last year and has been appointed by CEO, Scott Carr as new chair of the CAB. MacKeen previously served as Medical Imaging Specialist for The Hospital for Sick Children in Toronto, and Phoenix where she served as a MICRON application specialist from 2012 – 2013. In all, MacKeen has 28 years of ophthalmic imaging experience, 10 years of it with Clarity (now Natus) where she served as Ophthalmic Imaging Specialist / Clinical Services Manager. During her time at Clarity, MacKeen designed the MacKeen Pediatric Lid Speculum as well as an imaging training manikin; she also developed and conducted extensive training procedures and practices for the company.
“Phoenix is so fortunate to have recruited such a talented, hi-level panel of experts.” says MacKeen. “Their real-world insights, experience and expertise help us strengthen our decisions as we identify opportunities and offer solutions that are of value to our customers and their patients. I am looking forward to working with all of our members in this capacity as we deliver our products to the market.”
Other members of the Clinical Advisory Board include:
- Audina Berrocal, M.D.
- Susmito Biswas, MB BS, FRCOphth
- Sandor Ferenczy, B.S., CRA, OCT-C
- M. Edward Guthrie, M.D.
- Domenico Lepore, M.D.
- Michael Trese, M.D.
About Phoenix Technology Group: Phoenix Technology Group™ empowers people to see: we empower researchers to see more in their fight to prevent blindness; we empower clinicians to see more in their fight to save sight. We do that by providing clinicians and researchers around the world with stunning retinal images, coupled with timely and accurate data about the retina and the eye. Founded by Bert Massie, Ph.D., inventor of the first digital camera for pediatric retinal imaging, our company created the Phoenix MICRON™ platform for in-vivo imaging of animals in eye research. Phoenix MICRON™ is the standard of excellence for researchers worldwide: ten of the top twelve research institutions employ a Phoenix MICRON™ solution. In 2017, the company launched to great acclaim the Phoenix ICON™ platform which reinvented wide-field retinal imaging for human clinical applications. Phoenix ICON™ delivers stunning high-contrast, high-resolution images, with quality you can see and data you can trust. The Phoenix ICON™ platform also boasts a number of features including a lighter weight cart and a six-hour battery life. Recognizing that telemedicine is the future of ROP screening, in 2018, Phoenix launched Phoenix CONNECT, which today is the most widely adopted telemedicine platform for ROP screening. Phoenix CONNECT connects the nursing, ophthalmology, and neonatology teams to enable delivery of the best care by facilitating timely expert screening to babies in any NICU. And, the platform implements a proven screening workflow that generates critical photo documentation to enhance treatment determination and reduce risk.
Contact: Jen King, Phoenix Technology Group, ph.1.925.485.1100 x 244, email@example.com
For the original version on PRWeb visit: https://www.prweb.com/releases/phoenix_technology_group_announces_additions_to_the_clinical_advisory_board_and_appoints_new_chair/prweb16767777.htm